Skye Bioscience annual shareholders’ equity
2012
2013
2013
2014
2015
2016
2017
2018
2019
2019
2020
2021
2022
2023
2024
2025
Skye Bioscience Shareholders’ Equity Growth & History (SKYE)
Skye Bioscience's shareholders’ equity was $20.0M for fiscal 2025.
View full Skye Bioscience company overviewSkye Bioscience annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $20.0M | −$48.1M | −70.62% |
| 2024 | 2024-12-31 | $68.2M | $70.3M | — |
| 2023 | 2023-12-31 | −$2.1M | $876,236 | — |
| 2022 | 2022-12-31 | −$3.0M | −$8.9M | — |
| 2021 | 2021-12-31 | $5.9M | $5.4M | +1200.88% |
| 2020 | 2020-12-31 | $450,786 | −$97,272 | −17.75% |
| 2019 · Mar 31 | 2020-03-31 | −$1.7M | — | — |
| 2019 · Dec 31 | 2019-12-31 | $548,058 | $16.1M | — |
| 2018 | 2018-12-31 | −$15.6M | −$12.0M | — |
| 2017 | 2017-12-31 | −$3.6M | −$655,271 | — |
| 2016 | 2016-12-31 | −$2.9M | −$2.0M | — |
| 2015 | 2015-12-31 | −$892,204 | −$438,656 | — |
| 2014 | 2014-12-31 | −$453,548 | −$271,395 | — |
| 2013 · Dec 31 | 2013-12-31 | −$182,153 | — | — |
| 2013 · Oct 31 | 2013-10-31 | $83,377 | $44,818 | +116.23% |
| 2012 | 2012-10-31 | $38,559 | — | — |
Skye Bioscience quarterly shareholders’ equity
Q4.12
Q2.13
Q3.13
Q4.13
Q4.13
As of Jan 31, 2014
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q4.19
Q1.20
Q2.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$497,307 | −$44.2M | — |
| Q1 2026 | 2026-03-31 | $9.0M | −$50.2M | −84.79% |
| Q4 2025 | 2025-12-31 | $20.0M | −$48.1M | −70.62% |
| Q3 2025 | 2025-09-30 | $32.8M | −$43.0M | −56.68% |
| Q2 2025 | 2025-06-30 | $43.7M | −$29.1M | −40.01% |
| Q1 2025 | 2025-03-31 | $59.3M | −$19.6M | −24.89% |
| Q4 2024 | 2024-12-31 | $68.2M | $70.3M | — |
| Q3 2024 | 2024-09-30 | $75.8M | $74.1M | +4371.49% |
| Q2 2024 | 2024-06-30 | $72.8M | $80.6M | — |
| Q1 2024 | 2024-03-31 | $78.9M | $83.7M | — |
| Q4 2023 | 2023-12-31 | −$2.1M | $876,236 | — |
| Q3 2023 | 2023-09-30 | $1.7M | $5.0M | — |
| Q2 2023 | 2023-06-30 | −$7.8M | −$7.5M | — |
| Q1 2023 | 2023-03-31 | −$4.8M | −$7.8M | — |
| Q4 2022 | 2022-12-31 | −$3.0M | −$8.9M | — |
| Q3 2022 | 2022-09-30 | −$3.3M | −$11.5M | — |
| Q2 2022 | 2022-06-30 | −$301,822 | −$2.6M | — |
| Q1 2022 | 2022-03-31 | $3.0M | $494,443 | +19.95% |
| Q4 2021 | 2021-12-31 | $5.9M | $5.4M | +1200.88% |
| Q3 2021 | 2021-09-30 | $8.3M | $6.4M | +345.93% |
| Q2 2021 | 2021-06-30 | $2.3M | $5.4M | — |
| Q1 2021 | 2021-03-31 | $2.5M | $4.2M | — |
| Q4 2020 | 2020-12-31 | $450,786 | −$97,272 | −17.75% |
| Q2 2020 | 2020-09-30 | $1.9M | $18.3M | — |
| Q1 2020 | 2020-06-30 | −$3.1M | $8.5M | — |
| Q4 2019 · Mar 31 | 2020-03-31 | −$1.7M | $26.2M | — |
| Q4 2019 · Dec 31 | 2019-12-31 | $548,058 | $16.1M | — |
| Q3 2019 | 2019-09-30 | −$16.4M | −$6.2M | — |
| Q2 2019 | 2019-06-30 | −$11.6M | −$3.4M | — |
| Q1 2019 | 2019-03-31 | −$27.9M | −$22.1M | — |
| Q4 2018 | 2018-12-31 | −$15.6M | −$12.0M | — |
| Q3 2018 | 2018-09-30 | −$10.2M | −$6.9M | — |
| Q2 2018 | 2018-06-30 | −$8.2M | −$5.3M | — |
| Q1 2018 | 2018-03-31 | −$5.8M | −$2.9M | — |
| Q4 2017 | 2017-12-31 | −$3.6M | −$655,271 | — |
| Q3 2017 | 2017-09-30 | −$3.2M | −$850,697 | — |
| Q2 2017 | 2017-06-30 | −$2.9M | −$1.3M | — |
| Q1 2017 | 2017-03-31 | −$2.9M | −$509,185 | — |
| Q4 2016 | 2016-12-31 | −$2.9M | −$2.0M | — |
| Q3 2016 | 2016-09-30 | −$2.4M | −$1.8M | — |
| Q2 2016 | 2016-06-30 | −$1.6M | −$754,358 | — |
| Q1 2016 | 2016-03-31 | −$2.4M | −$2.0M | — |
| Q4 2015 | 2015-12-31 | −$892,204 | −$438,656 | — |
| Q3 2015 | 2015-09-30 | −$594,294 | −$1.4M | — |
| Q2 2015 | 2015-06-30 | −$861,015 | — | — |
| Q1 2015 | 2015-03-31 | −$338,356 | — | — |
| Q4 2014 | 2014-12-31 | −$453,548 | −$271,395 | — |
| Q3 2014 | 2014-09-30 | $776,288 | — | — |
| Q2 2014 | 2014-07-31 | $81,141 | $16,395 | +25.32% |
| Q1 2014 | 2014-04-30 | $73,381 | $7,793 | +11.88% |
| As of Jan 31, 2014 | 2014-01-31 | $86,997 | — | — |
| Q4 2013 · Dec 31 | 2013-12-31 | −$182,153 | — | — |
| Q4 2013 · Oct 31 | 2013-10-31 | $83,377 | $44,818 | +116.23% |
| Q3 2013 | 2013-07-31 | $64,746 | — | — |
| Q2 2013 | 2013-04-30 | $65,588 | — | — |
| Q4 2012 | 2012-10-31 | $38,559 | — | — |
Skye Bioscience shareholders’ equity trends
Over the last five fiscal years, Skye Bioscience's shareholders’ equity increased from $450,786 to $20.0M, a change of $19.6M. The latest reported quarter, Q2 2026, shows −$497,307.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Skye Bioscience source filings ↗